Welcome!

News Feed Item

Envisia Therapeutics Announces Appointments to Board of Directors

Envisia Therapeutics today announced that it has made two appointments to the company’s board of directors. Effective immediately, Adrienne Graves, Ph.D. and Gary Phillips, M.D. will join the board as non-executive members.

“We are extremely honored to have these two respected industry leaders join the Board of Directors of Envisia early in the lifecycle of our company, which we believe is paving the way for a potentially transformative line of innovative ocular therapeutics,” said Neal Fowler, Chief Executive Officer of Envisia Therapeutics. “Both appointments bring invaluable perspective and insights that are greatly complementary to that of our existing board, forming a team that will collectively help us position Envisia as a leader in developing cutting-edge solutions for the ophthalmology community.”

A global thought leader in ophthalmology, Dr. Adrienne Graves currently serves as an independent director on a number of corporate boards, including Akorn, Inc.; TearLab Corporation; Aerpio Therapeutics; and Encore Vision. She is also a director on a number of ophthalmology-related foundation boards, including the American Society of Cataract and Refractive Surgery (ASCRS) Foundation, Glaucoma Research Foundation (GRF), American Academy of Ophthalmology (AAO) Foundation (Emeritus), Himalayan Cataract Project, and KeepYourSight Foundation. Dr. Graves also cofounded Glaucoma 360 (Glaucoma Research Foundation) and Ophthalmic Women Leaders (OWL). Additionally, she serves on the Corporation Committee for the Brown University Medical School and the Advisory Board for Amach Capital Partners.

“Much progress has been made in the field of ophthalmology; however, the rate of preventable vision loss and blindness continues to rise and underscores the near-term need for truly innovative ocular therapies,” said Adrienne Graves, Ph.D. “Envisia’s application of the PRINT® technology to address unmet needs in ophthalmology could have a profound impact on our ability to reduce the rate of preventable vision loss, and I look forward to working with the company on its efforts to achieve this worthy goal.”

Dr. Graves was formerly President and Chief Executive Officer of Santen USA, a division of Santen Co. Ltd., Japan’s largest ophthalmic pharmaceutical company. She started her successful career with Santen USA in 1995 as Vice President of Clinical Affairs with responsibility for initiating the company’s U.S. clinical program, which included the approval of three New Drug Applications. Prior to joining Santen, she spent nine years with Alcon Laboratories, Inc., beginning as a Senior Scientist and then advancing into various roles, including Director of International Ophthalmology. Dr. Graves received her AB in Psychology with honors from Brown University and her Ph.D. in Psychobiology from the University of Michigan, and she completed a postdoctoral fellowship in visual neuroscience at the University of Paris.

Dr. Gary Phillips has more than 20 years’ experience in strategy, business development and licensing, commercial operations, business analytics, and clinical medicine in the pharmaceutical and healthcare industries. He is currently the Senior Vice President and Chief Strategy Officer at Mallinckrodt Pharmaceuticals.

“The ophthalmology market is attractive and highly concentrated among a few competitors; therefore, new entrants must be clearly differentiated through improved technologies that deliver marked improvement in patient outcomes while reducing the cost burden on patients and the healthcare system,” said Gary Phillips, M.D. “Through its unique combination of talent, technology, and vision, Envisia is well positioned to compete in this market, and I look forward to working with the company’s board and management team toward the goal of maximizing its potential in the years to come.”

Before joining Mallinckrodt, Dr. Phillips served as Head of Global Health and Healthcare Industries at the World Economic Forum in Geneva, Switzerland. Previously, he was President of Reckitt Benckiser Pharmaceuticals, Inc., and held the dual roles of President, U.S. Surgical and Pharmaceuticals and Global Head of Pharmaceuticals at Bausch & Lomb Incorporated. He has also held executive roles at Merck Serono, Novartis, and Wyeth (now Pfizer) and served as a healthcare strategy management consultant at Towers Perrin (now Towers Watson) and as a medical officer with the United States Navy. Dr. Phillips attended the University of Pennsylvania, where he earned a medical degree from the School of Medicine, an MBA from the Wharton School, and a Bachelor’s degree summa cum laude in biochemistry from the College of Arts and Sciences. He completed his postgraduate medical education at Naval Medical Center San Diego.

ABOUT ENVISIA THERAPEUTICS™

Envisia Therapeutics, formed by Liquidia Technologies in 2013, is a privately-held biotechnology company focused on the development of novel ocular therapies. Envisia is leveraging the unique and powerful properties of the PRINT® technology to develop therapies for a variety of ocular conditions, beginning with ENV515 for glaucoma. ENV515 is a novel, implantable extended-release formulation of travoprost (a marketed prostaglandin analogue) that has the potential to significantly limit disease progression and vision loss through improved product performance and patient compliance. Envisia is located in Research Triangle Park, North Carolina. For more information, please visit www.envisiatherapeutics.com.

More Stories By Business Wire

Copyright © 2009 Business Wire. All rights reserved. Republication or redistribution of Business Wire content is expressly prohibited without the prior written consent of Business Wire. Business Wire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
A strange thing is happening along the way to the Internet of Things, namely far too many devices to work with and manage. It has become clear that we'll need much higher efficiency user experiences that can allow us to more easily and scalably work with the thousands of devices that will soon be in each of our lives. Enter the conversational interface revolution, combining bots we can literally talk with, gesture to, and even direct with our thoughts, with embedded artificial intelligence, whic...
Every successful software product evolves from an idea to an enterprise system. Notably, the same way is passed by the product owner's company. In his session at 20th Cloud Expo, Oleg Lola, CEO of MobiDev, will provide a generalized overview of the evolution of a software product, the product owner, the needs that arise at various stages of this process, and the value brought by a software development partner to the product owner as a response to these needs.
SYS-CON Events announced today that Cloudistics, an on-premises cloud computing company, has been named “Bronze Sponsor” of SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. Cloudistics delivers a complete public cloud experience with composable on-premises infrastructures to medium and large enterprises. Its software-defined technology natively converges network, storage, compute, virtualization, and management into a ...
SYS-CON Events announced today that delaPlex will exhibit at SYS-CON's @ThingsExpo, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. delaPlex pioneered Software Development as a Service (SDaaS), which provides scalable resources to build, test, and deploy software. It’s a fast and more reliable way to develop a new product or expand your in-house team.
SYS-CON Events announced today that Technologic Systems Inc., an embedded systems solutions company, will exhibit at SYS-CON's @ThingsExpo, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. Technologic Systems is an embedded systems company with headquarters in Fountain Hills, Arizona. They have been in business for 32 years, helping more than 8,000 OEM customers and building over a hundred COTS products that have never been discontinued. Technologic Systems’ pr...
While some vendors scramble to create and sell you a fancy solution for monitoring your spanking new Amazon Lambdas, hear how you can do it on the cheap using just built-in Java APIs yourself. By exploiting a little-known fact that Lambdas aren’t exactly single threaded, you can effectively identify hot spots in your serverless code. In his session at 20th Cloud Expo, David Martin, Principal Product Owner at CA Technologies, will give a live demonstration and code walkthrough, showing how to ov...
With major technology companies and startups seriously embracing Cloud strategies, now is the perfect time to attend @CloudExpo | @ThingsExpo, June 6-8, 2017, at the Javits Center in New York City, NY and October 31 - November 2, 2017, Santa Clara Convention Center, CA. Learn what is going on, contribute to the discussions, and ensure that your enterprise is on the right path to Digital Transformation.
Most DevOps journeys involve several phases of maturity. Research shows that the inflection point where organizations begin to see maximum value is when they implement tight integration deploying their code to their infrastructure. Success at this level is the last barrier to at-will deployment. Storage, for instance, is more capable than where we read and write data. In his session at @DevOpsSummit at 20th Cloud Expo, Josh Atwell, a Developer Advocate for NetApp, will discuss the role and value...
SYS-CON Events announced today that Tappest will exhibit MooseFS at SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. MooseFS is a breakthrough concept in the storage industry. It allows you to secure stored data with either duplication or erasure coding using any server. The newest – 4.0 version of the software enables users to maintain the redundancy level with even 50% less hard drive space required. The software func...
New competitors, disruptive technologies, and growing expectations are pushing every business to both adopt and deliver new digital services. This ‘Digital Transformation’ demands rapid delivery and continuous iteration of new competitive services via multiple channels, which in turn demands new service delivery techniques – including DevOps. In this power panel at @DevOpsSummit 20th Cloud Expo, moderated by DevOps Conference Co-Chair Andi Mann, panelists will examine how DevOps helps to meet th...
SYS-CON Events announced today that EARP will exhibit at SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. "We are a software house, so we perfectly understand challenges that other software houses face in their projects. We can augment a team, that will work with the same standards and processes as our partners' internal teams. Our teams will deliver the same quality within the required time and budget just as our partn...
As DevOps methodologies expand their reach across the enterprise, organizations face the daunting challenge of adapting related cloud strategies to ensure optimal alignment, from managing complexity to ensuring proper governance. How can culture, automation, legacy apps and even budget be reexamined to enable this ongoing shift within the modern software factory?
SYS-CON Events announced today that Outscale will exhibit at SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. Outscale's technology makes an automated and adaptable Cloud available to businesses, supporting them in the most complex IT projects while controlling their operational aspects. You boost your IT infrastructure's reactivity, with request responses that only take a few seconds.
Most technology leaders, contemporary and from the hardware era, are reshaping their businesses to do software in the hope of capturing value in IoT. Although IoT is relatively new in the market, it has already gone through many promotional terms such as IoE, IoX, SDX, Edge/Fog, Mist Compute, etc. Ultimately, irrespective of the name, it is about deriving value from independent software assets participating in an ecosystem as one comprehensive solution.
In his keynote at @ThingsExpo, Chris Matthieu, Director of IoT Engineering at Citrix and co-founder and CTO of Octoblu, focused on building an IoT platform and company. He provided a behind-the-scenes look at Octoblu’s platform, business, and pivots along the way (including the Citrix acquisition of Octoblu).